TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A systematic review and meta-analysis covering nearly 16 million people found ADHD was associated with higher all-cause mortality and higher risks of suicide, injury and natural-cause death. ADHD medication use was associated with lower all-cause mortality, but that finding came from only three studies and may reflect differences between treated and untreated people.
A systematic review and meta-analysis of 19 studies covering nearly 16 million people found that attention-deficit/hyperactivity disorder (ADHD) was associated with a 71% higher risk of death from any cause than not having ADHD, consistent with research on health risks in adults with ADHD. The analysis also found higher risks of suicide, injury and natural-cause mortality; a separate association between ADHD medication and lower mortality was based on only three studies and cannot establish that medication caused the difference.
Researchers led by Joshua Stott, PhD, of University College London, reported an all-cause mortality hazard ratio of 1.71 for people with ADHD (95% confidence interval 1.31 to 2.24). The review, published in JAMA Network Open, included 19 studies with 15,920,970 participants. Twelve studies contributed data to the meta-analyses, which examined all-cause mortality, suicide, injury, natural-cause mortality and mortality among people using ADHD medication.
The analysis found higher rates of suicide mortality (hazard ratio 1.89), death from intentional or unintentional injury (1.55), and natural-cause mortality (1.27) among people with ADHD. These are associations reported across the included research; they do not show that ADHD alone caused any individual death. The authors said the included studies differed in the size of the measured associations, although each study showed higher mortality in its ADHD group.
For people with ADHD medication use, the pooled estimate suggested a 25% lower all-cause mortality risk (hazard ratio 0.75, 95% confidence interval 0.64 to 0.87). The researchers cautioned that this result drew on only three studies and could be affected by differences in health care access, illness severity, socioeconomic circumstances, treatment adherence and coexisting mental health conditions.
What the Mortality Findings Show
The results point to a broad health issue for people with ADHD, extending beyond the disorder’s core symptoms. The elevated estimates across suicide, injury and natural causes suggest that risks may arise through more than one pathway, and that clinicians and health systems may need to consider overall health and access to care when supporting patients with ADHD.
However, the figures describe group-level associations, not an individual’s prognosis. Stott told MedPage Today that the findings do not mean everyone with ADHD will die young or that increased mortality is inevitable. He said the results support making accurate diagnosis and treatment accessible to people who may have ADHD. The medication finding is not proof of a protective effect, given the small number of studies and the possibility that treated and untreated groups differ in important ways.
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Review
The authors assessed quantitative studies of ADHD and mortality across age groups, including research available through July 2025. ADHD status was identified in different ways across the literature, including diagnostic criteria, self-identification, symptom-trait measures and polygenic risk scores. The review drew on studies conducted across countries and populations, making differences in diagnosis and access to care relevant when interpreting the pooled results.
The report also notes that ADHD may be missed or diagnosed late, particularly in adults. Jeffrey Newcorn, MD, of the Icahn School of Medicine at Mount Sinai, who was not involved in the study, told MedPage Today that many adults are first diagnosed in adulthood and that many diagnosed adults do not receive treatment. The source report cites CDC estimates of 15 million U.S. adults with ADHD and 7 million children ages 3 to 17 with a diagnosis; these figures provide U.S. context but are not estimates from the mortality review.
Stott and colleagues discussed possible pathways rather than proving mechanisms. They pointed to impulsivity, emotional dysregulation and risk-taking as potential contributors to injury; depression and other coexisting conditions as possible factors in suicide risk; and smoking, alcohol use, barriers to health care, cardiovascular disease and metabolic disorders as possible contributors to natural-cause mortality.
“These findings do not suggest that everyone with ADHD will die young, nor do they suggest that increased mortality is impossible to change or inherent to ADHD.”
— Joshua Stott, PhD, lead researcher, speaking to MedPage Today
As an affiliate, we earn on qualifying purchases.
Limits of the Mortality Evidence
The findings are based on observational research, so the review cannot establish that ADHD itself caused the higher mortality or determine how much particular factors contributed. The studies used different ways to identify ADHD and varied in population and design. The authors reported substantial statistical heterogeneity in the first four mortality analyses, meaning estimates differed in magnitude across studies, even though the direction of association was consistent.
The medication result is especially uncertain: it was based on three studies, and the authors warned about residual confounding and confounding by indication. The review does not establish which treatments were used, whether medication exposure was consistent over time, or whether medication directly changed mortality risk. The source report also notes gender imbalances in many studies. The available findings do not settle how risks vary by age, sex, ADHD presentation, treatment history or access to care.
As an affiliate, we earn on qualifying purchases.
Questions for Future Research
The report does not announce a new trial or a specific next research milestone. Further studies would need to test whether the associations differ across age groups and populations and to account more fully for coexisting conditions, socioeconomic factors and access to care. Researchers would also need stronger evidence to determine whether ADHD medication is associated with a direct change in mortality risk or whether the observed difference reflects who receives treatment.
For now, the review adds pooled evidence to earlier studies but does not provide an individual risk estimate or a treatment recommendation. Its authors’ stated priority is access to accurate ADHD diagnosis and treatment; the specific effects of care on mortality remain an open research question.
ADHD safety and injury prevention products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
Did the study show that ADHD causes early death?
No. The review found an association between ADHD and higher mortality in the included studies. It cannot establish that ADHD itself caused the deaths or predict an individual’s outcome.
How much higher was all-cause mortality in the analysis?
The pooled estimate was a hazard ratio of 1.71, reported by the authors as a 71% higher all-cause mortality risk among people with ADHD compared with others. This is a group-level estimate, not a personal forecast.
Did ADHD medication lower the risk of death?
Medication use was associated with a lower all-cause mortality estimate, but that analysis included only three studies. The authors cautioned that differences between treated and untreated people could explain some or all of the association; the result does not prove medication causes lower mortality.
Which causes of death were higher in the review?
The meta-analysis reported higher mortality estimates for suicide, intentional or unintentional injury, and natural causes, as well as higher all-cause mortality. The review does not show that these risks apply equally to every person with ADHD.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
